首页|维D钙咀嚼片联合唑来膦酸对骨质疏松症的症状改善与血清炎性因子水平的影响

维D钙咀嚼片联合唑来膦酸对骨质疏松症的症状改善与血清炎性因子水平的影响

扫码查看
目的 分析维D钙咀嚼片联合唑来膦酸对骨质疏松症的症状改善与血清炎性因子水平的影响.方法 选取曹县人民医院于2019年3月—2023年3月收治的62例骨质疏松症患者为研究对象,以随机数表法分为对照组(n=31,唑来膦酸治疗)与观察组(n=31,维D钙咀嚼片联合唑来膦酸治疗),连续治疗3个月,比较两组症状改善时间、血清炎性因子水平.结果 观察组乏力、腰背疼痛及骨痛等症状改善时间分别为(5.55±1.85)、(7.42±1.63)、(8.07±1.93)d短于对照组的(7.32±1.23)、(11.18±2.72)、(13.96±2.67)d,差异有统计学意义(t=3.097、4.693、5.263,P均<0.05).治疗前,两组炎性因子水平[白细胞介素-6(Interleukin-6,IL-6)、肿瘤坏死因子-α(Tumor Necrosis Factor-α,TNF-α)、超敏C反应蛋白(Hypersensitive C-reactive Protein,hs-CRP)]、骨密度(Bone Mineral Density,BMD)及25羟基维生素D比较,差异无统计学意义(P均>0.05);治疗后,观察组炎性因子各项指标水平均低于对照组,差异有统计学意义(P均<0.05);两组BMD及25-羟基维生素D均较治疗前升高,且观察组BMD、25-羟基维生素D高于对照组,差异有统计学意义(P均<0.05).两组不良反应发生率比较,差异无统计学意义(P>0.05).结论 维D钙咀嚼片联合唑来膦酸能更好地改善骨质疏松症患者临床症状,降低血清炎性因子水平,提升骨密度与骨代谢水平.
Effects of Vitamin D Calcium Chewable Tablets Combined with Zole-dronic Acid on Symptom Improvement and Serum Inflammatory Factor Levels of Osteoporosis
Objective To analyze the effects of vitamin D calcium chewable tablets combined with zoledronic acid on the improvement of osteoporosis symptoms and the level of serum inflammatory factors.Methods Sixty-two patients with osteoporosis admitted to Caoxian People's Hospital from March 2019 to March 2023 were selected as the study objects,and they were divided into control group(n=31,zoledronic acid treatment)and observation group(n=31,vita-min D calcium chewable tablets combined with zoledronic acid treatment)by random number table method.Symptom improvement time and serum inflammatory factor levels were compared between the two groups.Results The improve-ment time of fatigue,low back pain and bone pain in the observation group was(5.55±1.85),(7.42±1.63),(8.07±1.93)d,respectively,which was shorter than that of the control group(7.32±1.23),(11.18±2.72),(13.96±2.67)d,and the differ-ences were statistically significant(t=3.097,4.693,5.263,all P<0.05).Before treatment,there were no significant dif-ference in the levels of inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),hypersensitive C-reactive protein(hs-CRP)],bone mineral density(BMD)and 25 hydroxyvitamin D(all P>0.05).After treatment,the levels of inflammatory factors in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).BMD and 25-hydroxyvitamin D in both groups were higher than those before treatment,and BMD and 25-hydroxyvitamin D in observation group were higher than those in control group,and the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Vitamin D calcium chewable tablets combined with zole-dronic acid can better improve the clinical symptoms of osteoporosis patients,reduce the level of serum inflammatory factors,improve the level of bone mineral density and bone metabolism.

Vitamin D calcium chewable tabletsZoledronic acidOsteoporosisSerum inflammatory factor

李招霞、王柯、赵青

展开 >

曹县人民医院内分泌科,山东菏泽 274400

维D钙咀嚼片 唑来膦酸 骨质疏松症 血清炎性因子

2024

系统医学

系统医学

ISSN:
年,卷(期):2024.9(7)
  • 13